FDA issues top risk recall for thyroid drug

The FDA has classified a recall of one lot of Vitruvias Therapeutics' 30 mg thyroid tablets as a Class I, the highest risk level, due to potential superpotency. Distributed nationwide between January and September 2025, about 1,900 units are affected, which could cause serious health issues such as overactive thyroid symptoms. Consumers are advised to contact healthcare providers before stopping the medication and can reach out to Vitruvias for further guidance.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل